Bausch Health: The Xifaxan Countdown Meets a Margin Miracle

A Quarter of Milestones

Bausch Health's Q2 2026 was anything but routine. The company notched its 13th consecutive quarter of top-line and bottom-line growth, with CEO Thomas Appio declaring: “We grew revenue 16% and adjusted EBITDA 28%, our highest growth for both metrics in the last 3 years.” — Thomas Appio, Chief Executive Officer · 2026-07-29 Consolidated revenue reached $2.852 billion, driven by a 21% surge in the Salix segment and a 38% jump in Solta, while adjusted EBITDA rose 28% to $1.075 billion. CFO from operations hit $637 million, up 44% year-over-year.

The strongest signal, though, is the segment profit expansion: the ex-Bausch + Lomb business grew segment profit 19% outside Salix, and Solta's segment profit rose 69% on a reported basis. CFO Jean-Jacques Charhon highlighted the structural change: “Solta recorded a segment profit of $91 million in the second quarter, which was the first true indicator of the value accretion associated with the integration of our full-service distributor in China.” — Jean-Jacques Charhon, Chief Financial Officer · 2026-07-29 Management now sees a full-year run-rate of $330 million for Solta, a $100 million increase from 2025 — a meaningful step-change that the market has yet to fully price.

The Shibo Integration and Solta's New Engine

Solta's acceleration is the quarter's most important strategic development. The integration of Shibo, its full-service distributor in China, has transformed the economics. Revenue in China grew 136% year-over-year, and the company is also seeing strong momentum in South Korea (up 8%) and Taiwan (up 42%). The margin accretion is not a one-off: J.J. Charhon noted that

management believes that the full-year run rate for Solta segment profit now stands at approximately $330 million, which is approximately a $100 million increase when compared to 2025.

But to put the quarter in context, the stock is still trading at just 0.2x price-to-revenue, down ~97% from its 2015 peak. The market remains fixated on the Xifaxan overhang — the drug that generates the bulk of Salix's profit faces a massive IRA rebate in 2027 and a potential generic entry in 2028. On the call, J.J. reiterated the 2027 EBITDA guidance of $2.7 billion, which implies a meaningful step-down from the 2026 midpoint of ~$3.06 billion. That guidance assumes Xifaxan exclusivity until January 1, 2028, and includes the incremental CMS rebate. As he said, “You should be able to deduce fairly easily what is the magnitude of the additional rebate associated with CMS.” — Jean-Jacques Charhon, Chief Financial Officer · 2026-07-29 This is the same story we've heard for two years — and the company is using the time to build out other engines.

Business Development and the B+L Option

Beyond Solta, the company continues to emphasize business development as a core value lever. Thomas Appio reaffirmed that cardiometabolic franchise growth in LATAM and EMEA is a template for tuck-in acquisitions, and the DURECT acquisition (larsucosterol for alcohol-associated hepatitis) provides a platform for new indications. The CFO noted two distinct paths: small development-stage assets like DURECT, or larger near-commercial products with quick synergies. On the capital structure, the company reduced net debt by $434 million in the quarter, ending at $13.7 billion, and the continued Cash flow from operations strength is allowing it to self-fund these investments.

Management's patience on monetizing Bausch + Lomb is notable. J.J. Charhon explained that the recent refinancing gives them flexibility: “The objective was to extend the runway… Therefore increase flexibility around the timing in the process, we might decide to fully realize the value of our B+L asset for BHC shareholders.” — Jean-Jacques Charhon, Chief Financial Officer · 2026-07-29 This echoes the prior quarter's framing, where he noted the most probable outcome is a sale of the equity stake. The market is waiting for the next observable milestone, but the company is clearly in a stronger position to wait for the right valuation.

The quarter also underscored the resilience of the underlying business: ex-B+L revenue grew 16%, with International up 5% organically (LATAM +16%) and cardiometabolic launches contributing. This breadth is why the guidance raise was so confident — the company now expects full-year revenue of $5.35–5.50 billion and EBITDA of $3.025–3.100 billion, up $150 million at the midpoint. As Appio summed it up: “We delivered a very strong first half, growing revenue and adjusted EBITDA respectively 15% and 23%.” — Thomas Appio, Chief Executive Officer · 2026-07-29